Research summary
Research HubCerebrolysin
Review — 10 studies
Cerebrolysin is a mixture of peptides obtained from pig brain protein, examined in clinical trials in stroke, dementia and traumatic brain injury. Most of its cited evidence is pooled analysis of those trials, with two animal studies alongside.
Updated
Being studied for
- Acute ischaemic stroke trials
- Vascular and Alzheimer's dementia trials
- Traumatic brain injury trials
- Spinal cord ischaemia models
- Dendritic spine structure in aged mice
What the research shows
Seven of the ten citations are pooled analyses of clinical trials: four Cochrane reviews (2013, 2017, 2019 and 2020) and three other meta-analyses, together covering acute ischaemic stroke, vascular dementia, Alzheimer's disease and the CAPTAIN trial series in traumatic brain injury. The other three are a 2025 paper on psychiatric disorders and two animal studies, in aged mice (2025) and in a rabbit model of spinal cord ischaemia-reperfusion injury (2023).
Results differ by condition. In acute ischaemic stroke, the 2017 Cochrane review found no demonstrated clinical advantage and the 2020 review found little or no effect on death from any cause; both reported moderate-quality evidence of an increase, or a possible increase, in non-fatal serious adverse events. A separate 2017 meta-analysis concluded that routine use in acute ischaemic stroke was not supported by randomised trial evidence. In vascular dementia, the 2013 and 2019 Cochrane reviews reported positive effects on cognition and general function but judged the evidence insufficient or not definitive. A 2015 meta-analysis in mild to moderate Alzheimer's disease and the 2021 prospective meta-analysis of the CAPTAIN trials in moderate to severe traumatic brain injury both reported pooled results in cerebrolysin's favour. The 2025 psychiatry paper concluded that the compound's place in psychiatry could be relatively small.
In animals, a 2025 study in aged mice reported greater dendritic spine maturation and less age-related memory decline, and a 2023 rabbit study of spinal cord ischaemia-reperfusion injury reported anti-inflammatory, antioxidant and anti-apoptotic effects.
Read together, the reviews do not point one way. The stroke analyses are neutral or negative and flag non-fatal serious adverse events; the vascular dementia reviews are cautiously positive but cite few trials, varied durations, short follow-up, heterogeneity and a high risk of bias; and the most positive conclusions come from single meta-analyses in Alzheimer's disease and traumatic brain injury. Each animal finding rests on one study.
Published Research
Evidence profile
Predominantly preclinical
10 cited publications
Findings below belong to the studies that reported them. They describe the material and conditions those authors used, not this product, and not an outcome to expect.
Supporting evidence
Cerebrolysin after moderate to severe traumatic brain injury: prospective meta-analysis of the CAPTAIN trial series
Vester JC et al. · Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2021
The study reportedThe meta-analysis of the CAPTAIN trials confirms the safety and efficacy of Cerebrolysin after moderate-severe TBI, opening a new horizon for neurorecovery in this field. Integration of Cerebrolysin into existing guidelines should be considered after careful review of internationally applicable criteria.
Cerebrolysin for acute ischaemic stroke
Ziganshina LE et al. · The Cochrane database of systematic reviews · 2020
The study reportedModerate-quality evidence indicates that Cerebrolysin probably has little or no beneficial effect on preventing all-cause death in acute ischaemic stroke, or on the total number of people with serious adverse events. Moderate-quality evidence also indicates a potential increase in non-fatal serious adverse events with Cerebrolysin use.
Cerebrolysin for vascular dementia
Cui S et al. · The Cochrane database of systematic reviews · 2019
The study reportedCourses of intravenous Cerebrolysin improved cognition and general function in people living with vascular dementia, with no suggestion of adverse effects. However, these data are not definitive. Our analyses were limited by heterogeneity, and the included papers had high risk of bias.
Cerebrolysin for acute ischaemic stroke
Ziganshina LE et al. · The Cochrane database of systematic reviews · 2017
The study reportedThe findings of this Cochrane Review do not demonstrate clinical benefits of cerebrolysin for treating acute ischaemic stroke. We found moderate-quality evidence of an increase in non-fatal SAEs with cerebrolysin use but not in total SAEs.
Cerebrolysin for functional recovery in patients with acute ischemic stroke: a meta-analysis of randomized controlled trials
Wang Z et al. · Drug design, development and therapy · 2017
The study reportedIn safety analysis, cerebrolysin did not increase the risk of adverse events (RR 0.98, 95% CI 0.88-1.09, P=0.67), risk of serious adverse events (RR 1.20, 95% CI 0.86-1.66, P=0.29), or the mortality rate (RR 0.86, 95% CI 0.57-1.31, P=0.49).
Cerebrolysin in mild-to-moderate Alzheimer's disease: a meta-analysis of randomized controlled clinical trials
Gauthier S et al. · Dementia and geriatric cognitive disorders · 2015
The study reportedThis meta-analysis provides evidence that Cerebrolysin has an overall beneficial effect and a favorable benefit-risk ratio in patients with mild-to-moderate AD. Cerebrolysin as a therapeutic agent should be considered by clinicians seeking treatment options for mild-to-moderate AD.
Cerebrolysin for vascular dementia
Chen N et al. · The Cochrane database of systematic reviews · 2013
The study reportedCerebrolysin may have positive effects on cognitive function and global function in elderly patients with vascular dementia of mild to moderate severity, but there is still insufficient evidence to recommend Cerebrolysin as a routine treatment for vascular dementia due to the limited number of included trials, wide variety of treatment durations and short-term follow-up in most of the trials.
Additional indexed literature (3)
- Review · Mechanistic studyIs Cerebrolysin Useful in Psychiatry Disorders?
Florek S et al. · Biomedicines · 2025 · PMID 40722733
- Preclinical · Mechanistic studyCerebrolysin Ameliorates Age-Induced Dendritic Spine Degeneration and Memory Decline in C57BL6 Mice
Aguilar-Hernández L et al. · Neurochemical research · 2025 · PMID 41460391
- Preclinical · Mechanistic studyCerebrolysin Amelioration of Spinal Cord Ischemia/ Reperfusion Injury in Rabbit Model
Tonge C et al. · Turkish neurosurgery · 2023 · PMID 37309634
Published studies summarised here concern the specific investigational or pharmaceutical materials and study conditions described by their authors. Their findings are not performance claims for Cobalt Peptides material. Citations verified against PubMed on 2026-09-29.
Cerebrolysin's clinical and research use is regional, and it does not hold approval in every jurisdiction.
Notice
All information on this page is provided strictly for laboratory research and educational purposes only.